Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID) infections in persons who inject drugs.

Injection drug use poses a public health challenge. Clinical experience indicates that people who inject drugs (PWID) are hospitalized frequently for infectious diseases, but little is known about outcomes when admitted. Charts were identified from local hospitals between 2013-2018 using consultation lists and hospital record searches. Included individuals injected drugs in the past six months and presented with infection. Charts were accessed using the hospital information system, undergoing primary and secondary reviews using Research Electronic Data Capture (REDCap). The Wilcoxon rank-sum test was used for comparisons between outcome categories. Categorical data were summarized as count and frequency, and compared using Fisher's exact test. Of 240 individuals, 33% were admitted to the intensive care unit, 36% underwent surgery, 12% left against medical advice (AMA), and 9% died. Infectious diagnoses included bacteremia (31%), abscess (29%), endocarditis (29%), cellulitis (20%), sepsis (10%), osteomyelitis (9%), septic arthritis (8%), pneumonia (7%), discitis (2%), meningitis/encephalitis (2%), or other (7%). Sixty-six percent had stable housing and 60% had a family physician. Fifty-four percent of patient-initiated discharges were seen in the emergency department within 30 days and 29% were readmitted. PWID are at risk for infections. Understanding their healthcare trajectory is essential to improve their care.

Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease.

BACKGROUND AND AIM: Vedolizumab is a novel monoclonal antibody used in patients with inflammatory bowel disease, often affecting women of child-bearing age. We aimed to compare maternal and fetal adverse outcomes in pregnancies of women with inflammatory bowel disease exposed to vedolizumab versus those on other treatment. METHODS: We performed a systematic literature search through December 2020 looking for studies including outcomes from pregnancies of female inflammatory bowel disease patients treated with vedolizumab. Our primary outcome was a composite of adverse pregnancy-related events in pregnancies of female patients on vedolizumab compared with those of disease-matched controls on other medication regimens. Events of interest included preterm births, early loss of pregnancy, late fetal death, elective termination of pregnancy, and congenital anomalies. RESULTS: Four studies were included in our review meeting criteria for our primary analysis. Compared with those with no vedolizumab exposure, pregnancies with vedolizumab exposure had an increase in overall adverse pregnancy-related outcomes (odds ratio [OR] 2.18, 95% confidence interval [CI], 1.52-3.13). The vedolizumab group also had increased preterm births (OR 2.16, 95% CI, 1.28-3.66), and early loss of pregnancies (OR 1.79, 95% CI, 1.06-3.01) but no difference in number of live births (OR 0.60, 95%CI, 0.36-1.00), or congenital malformations (OR 1.56, 95% CI, 0.56-4.37). CONCLUSIONS: Our systematic review highlights possible concern with the general safety of vedolizumab in pregnancy, as an increase in overall total unfavorable outcomes was observed. Premature births and early loss of pregnancy were also more prevalent in pregnant female patients on vedolizumab. It is possible these findings are confounded by disease activity, and further prospective cohort studies of vedolizumab and pregnancy outcomes are warranted.

Risk of Severe Maternal Morbidity or Death in Relation to Prenatal Biochemical Screening: Population-Based Cohort Study.

OBJECTIVE: This study aimed to examine whether prenatal biochemical screening analytes are associated with an increased risk of severe maternal morbidity (SMM) or maternal mortality. STUDY DESIGN: This population-based cohort study includes all women in Ontario, Canada, who underwent prenatal screening from 2001 to 2011. Increasing fifth percentiles of the multiple of the median (MoM) for alphafetoprotein (AFP), total human chorionic gonadotropin, unconjugated estriol (uE3), dimeric inhibin-A (DIA), and pregnancy-associated plasma protein A were evaluated. An abnormally high concentration (>95th percentile MoM) for each analyte, individually and combined, was also evaluated. The main outcome assessed was the adjusted relative risk (aRR) of SMM or maternal mortality from 20 weeks' gestation up to 26 weeks thereafter. RESULTS: Among 748,972 pregnancies, 11,177 resulted in SMM or maternal mortality (1.5%). Except for uE3, the aRR of SMM or maternal mortality increased in association with increasing fifth percentiles of the MoM for all analytes. AFP (aRR: 2.10; 95% confidence interval [CI]: 1.97-2.25) and DIA (aRR: 2.33; 95% CI: 1.98-2.74) > 95th versus ≤ 5th percentile of the MoM were especially associated with SMM or death. CONCLUSION: Women with abnormally high concentrations of certain prenatal biochemical analytes may be at a higher risk of SMM or death in pregnancy or postpartum.

Association Between Web-Based Physician Ratings and Physician Disciplinary Convictions: Retrospective Observational Study.

BACKGROUND: Physician rating websites are commonly used by the public, yet the relationship between web-based physician ratings and health care quality is not well understood. OBJECTIVE: The objective of our study was to use physician disciplinary convictions as an extreme marker for poor physician quality and to investigate whether disciplined physicians have lower ratings than nondisciplined matched controls. METHODS: This was a retrospective national observational study of all disciplined physicians in Canada (751 physicians, 2000 to 2013). We searched ratings (2005-2015) from the country's leading online physician rating website for this group, and for 751 matched controls according to gender, specialty, practice years, and location. We compared overall ratings (out of a score of 5) as well as mean ratings by the type of misconduct. We also compared ratings for each type of misconduct and punishment. RESULTS: There were 62.7% (471/751) of convicted and disciplined physicians (cases) with web-based ratings and 64.6% (485/751) of nondisciplined physicians (controls) with ratings. Of 312 matched case-control pairs, disciplined physicians were rated lower than controls overall (3.62 vs 4.00; P<.001). Disciplined physicians had lower ratings for all types of misconduct and punishment-except for physicians disciplined for sexual offenses (n=90 pairs; 3.83 vs 3.86; P=.81). Sexual misconduct was the only category in which mean ratings for physicians were higher than those for other disciplined physicians (3.63 vs 3.35; P=.003). CONCLUSIONS: Physicians convicted for disciplinary misconduct generally had lower web-based ratings. Physicians convicted of sexual misconduct did not have lower ratings and were rated higher than other disciplined physicians. These findings may have future implications for the identification of physicians providing poor-quality care.

Preeclampsia Brings the Risk of Premature Cardiovascular Disease in Women Closer to That of Men.

BACKGROUND: It is not known if sex differences in the risk of premature cardiovascular disease (CVD) vary by whether a woman had preeclampsia or not. The current study determined whether prior preeclampsia brings a woman's risk of CVD closer to that of a male counterpart. METHODS: A population-based cohort study was completed in Ontario, Canada, from 1993 to 2017. Participants were 55,186 women with prior preeclampsia, 110,372 randomly selected age- and region-matched men, and 110,372 similarly selected women who gave birth without prior preeclampsia. The primary outcome was a CVD composite outcome of any hospitalization or revascularization for coronary artery disease, cerebrovascular disease, peripheral artery disease, heart failure, and dysrhythmia. RESULTS: Median follow-up was approximately 16 years. Relative to women without prior preeclampsia (1193 events; 7.5 per 10,000 person-years), men had the highest risk of CVD (3706 events; 24.3 per 10,000 person-years) (adjusted hazard ratio [aHR], 2.52; 95% confidence interval [CI], 2.35-2.69). Women with a history of preeclampsia were also at higher risk (1252 events; 16.0 per 10,000 person-years) (aHR, 1.17; 95% CI, 1.08-1.28). Women with preeclampsia requiring preterm delivery were even more likely to experience CVD (21.5 per 10,000 person-years) (aHR, 1.44; 95% CI, 1.18-1.76). The absolute risk of CVD in men (22.5 per 10,000 person-years) was similar to the risk in women with preeclampsia and preterm delivery, but men had the highest aHR (2.48; 95% CI, 2.11-2.93). CONCLUSIONS: Although men remain at significantly higher risk of CVD, a history of preeclampsia, especially with preterm birth, elevates a woman's risk closer to that of a man.

Structure of Antimicrobial Stewardship Programs in Leading US Hospitals: Findings of a Nationwide Survey.

BACKGROUND: To examine antibiotic stewardship program (ASP) structure among high-performing hospitals and determine which components of the 2016 Infectious Diseases Society of America (IDSA)/Society for Hospital Epidemiology of America (SHEA) ASP guidelines are implemented at each site. METHODS: A survey of the highest-ranking hospitals, compiled from the 2015-2016 US News and World Report's Best Hospital Rankings, was conducted from August to December 2016. This corresponded to 138 adult and 62 pediatric unique hospitals. We inquired as to which components of the 2016 IDSA/SHEA ASP guidelines were implemented at each site. Appropriate persons at each hospital were emailed surveys after telephone or email conversations confirmed that they belonged to that hospital's ASP. RESULTS: Overall, 101 of 200 hospitals responded (51%). Of these, 82% (n = 83/101) had an active ASP, and 59% (n = 47/80) were active for more than 5 years. Most report to a committee rather than to an individual (n = 68/80, 85%), do not have their own budget (n = 42/80, 53%), and selectively implement IDSA/SHEA recommendations. Additionally, the majority of ASPs in top hospitals follow aspects of The Joint Commission Standards for Antimicrobial Stewardship, which were released after the survey was administered. CONCLUSIONS: Of leading US hospitals responding to our survey, >80% had an ASP, and most implemented the majority of commitments, interventions, and optimization strategies suggested by IDSA/SHEA. Understanding the structure of ASPs in these hospitals will assist other hospitals in program implementation.